If the Biden drug plan passes, the United States will be consciously volunteering to put less capital to work in a large industry where we lead the world. No real argument can stand against the fact that less capital means fewer new products for patients.

Given the seemingly endless supply of COVID-19-related content, it has sometimes felt like I was passively binging on round-the-clock coverage that was more distracting than edifying. So what might I have missed while I was absorbed in COVID? As it turns out, quite a lot.

The U.S. biotechnology sector is an indispensable, strategic national asset. But what if we’re taking it for granted? Recent attempts to weaken IP protections for Covid-19 vaccines and to implement drug price controls threaten future U.S. leadership in biotechnology.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

The way that hospitals benefit from inflated list prices is a common theme across different kinds of drugs dispensed at hospitals and clinics across the country. When drug prices are a Trojan Horse for all kinds of other health care costs, we all lose.

Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.

There are many ways to conduct an efficient board meeting, and every management team and board member has different preferences. But here are four key principles I believe will improve everyone’s experience.

The so-called venture creation model has fully taken root, underpinned and enabled by biotech's longest-ever boom cycle and unprecedented sums of available capital.

Adam Rosenberg lifts the curtain on what biotech venture partners and entrepreneurs-in-residence really do.

The difference between investing in space exploration and investing in the biotech industry is about who bears the cost: society as a whole or people as individuals.

Repatriating the American drug supply is key not just to averting shortages but to restoring and preserving the integrity of generic drugs in America.

ICER released a report concluding that Vertex’s groundbreaking triple-combination cystic fibrosis (CF) drug, Trikafta, is too expensive for the value it provides to patients. But is it?

Whatever therapy or intervention solves a previously unmet need is inherently novel. So any treatments for COVID-19 that turn out to work will be "novel" in every way that matters.